Data demonstrates the significant and sustained tumor regression achieved by the CAPTN-3 platform across two distinct tri-specific antibodies, IM1240 and IM1305, targeting different tumor antigens Transcriptomic analysis across ~11,000 TCGA samples shows NKG2A expression is strongly associated with tumor expression of 5T4 or TROP2, supporting inclusion of the NKG2A arm in CAPTN-3 designs NKG2A arm significantly contributes to IM1240 anti-cancer immune activity in PD1-resistant patient-derived explants REHOV ...

New data showcase the versatility and anti-tumor activity of the CAPTN-3 platform and its unique multi-arm design in treatment-resistant cancers     REHOVOT, Israel, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced that it will present new preclinical data from its CAPTN-3 platform of conditionally activated ...

Core Insights - Purple Biotech Ltd. has initiated the development of a second tri-specific antibody, IM1305, targeting TROP2, and achieved a manufacturing milestone for its first tri-specific antibody, IM1240, which targets 5T4 [1][4] - The company reported a cash position of $10.5 million as of September 30, 2025, with an expected cash runway into the first half of 2027, supporting the development of its CAPTN-3 technology platform [1][10] Financial Performance - Research and Development Expenses for the three months ended September 30, 2025, were $0.6 million, a decrease of 56.4% from $1.3 million in the same period of 2024, primarily due to reduced costs associated with the CM24 Phase 2 study [5] - General and Administrative Expenses remained consistent at $0.8 million for the three months ended September 30, 2025, compared to the same period in 2024 [6] - The Operating Loss for the three months ended September 30, 2025, was $1.4 million, a decrease of 35.8% from $2.1 million in the same period of 2024 [6] - The Net Loss for the three months ended September 30, 2025, was $1.3 million, or $0.29 per basic and diluted ADS, compared to a net loss of $0.7 million, or $0.39 per basic and diluted ADS, in the same period of 2024 [9] Clinical and Corporate Developments - The company plans to conduct non-GLP and GLP toxicology studies, submit an Investigational New Drug application (IND), and initiate a Phase 1 study for IM1240 in 2026 [2] - IM1240 has demonstrated tumor cell death in patient-derived, treatment-resistant head and neck biopsies, advancing toward first-in-human clinical trials [4] - The CM24 Phase 2 study will utilize identified biomarkers for patient selection in the upcoming Phase 2b study, which is subject to partnering [4] Patent and Intellectual Property - Purple Biotech received an intention to grant a European patent covering NT219 combinations with immunotherapies or MEK inhibitors to overcome tumor resistance [3][5]

Group 1: Stock Price Movements - Globalink Investment Inc. experienced a significant surge, with its stock price jumping to $0.09, marking a 581.82% increase, driven by heightened investor interest possibly due to speculative activities or potential business combination news [1][6] - Cambium Networks Corporation saw its stock price rise to $2.66, a 331.65% increase, attributed to the integration of its Cambium ONE Network solution with Starlink satellite Internet services, enhancing its growth prospects [2][6] - Purple Biotech Ltd. witnessed its stock price increase to $0.93, up by 59.74%, driven by promising updates on its clinical trials and strategic partnerships, particularly regarding its tri-specific antibody IM1240 [3][6] - Ernexa Therapeutics Inc. saw its price increase to $1.97, a 57.85% rise, influenced by investor optimism towards its innovative therapies and a partnership with Cellipont Bioservices for clinical trials [4][6] - VSee Health, Inc. experienced a 49.52% increase in its stock price to $0.17, reflecting growing investor interest in the telehealth sector amid ongoing healthcare trends [5] Group 2: Market Trends and Investor Sentiment - The stock movements underscore the dynamic nature of the market, where company-specific developments, sector trends, and broader economic factors significantly impact stock prices [5] - Investors and analysts closely monitor such changes to gauge market sentiment and identify potential investment opportunities [5]

Market Overview - U.S. stocks traded higher, with the Dow Jones index gaining approximately 250 points, up 0.55% to 47,970.89, NASDAQ rose 0.65% to 23,982.73, and S&P 500 increased by 0.33% to 6,913.53 [1] - Asian markets closed higher, with Japan's Nikkei 225 surging 2.17%, China's Shanghai Composite gaining 0.70%, and India's BSE Sensex up 0.44% [6] - European shares were mixed, with the eurozone's STOXX 600 gaining 0.1%, while Germany's DAX 40 fell 0.3% and France's CAC 40 decreased by 0.2% [5] Company Financials - Verizon Communications reported mixed third-quarter results, with a revenue growth of 1.5% year-over-year, reaching $33.8 billion, which missed the analyst consensus estimate of $34.3 billion. Adjusted EPS was $1.21, exceeding the consensus estimate of $1.19 [2] Commodity Prices - In commodity news, oil traded up 0.3% to $60.31, gold increased by 1% to $4,022.90, silver rose 1.6% to $48.075, and copper was up 1% to $5.2205 [4] Stock Movements - Cambium Networks Corp shares surged 209% to $1.91 after announcing integration with Starlink satellite Internet services [8] - Purple Biotech Ltd shares increased 118% to $1.27 following the achievement of a commercially viable yield for IM1240 [8] - Founder Group Ltd shares rose 54% to $0.69 [8] - Advent Technologies Holdings Inc shares dropped 51% to $1.33 [8] - Stride Inc shares fell 47% to $82.04 after providing second-quarter sales guidance below analyst estimates [8] - Varonis Systems Inc shares decreased 44% to $35.14 after reporting third-quarter revenue below estimates and providing fourth-quarter guidance below expectations [8] Economic Indicators - U.S. mortgage application volume jumped by 7.1% from the previous week in the period ending October 17 [7]

Market Overview - U.S. stocks traded higher, with the Dow Jones index gaining approximately 250 points, up 0.55% to 47,970.89, NASDAQ rose 0.65% to 23,982.73, and S&P 500 increased by 0.33% to 6,913.53 [1] - Asian markets closed higher, with Japan's Nikkei 225 surging 2.17%, China's Shanghai Composite gaining 0.70%, and India's BSE Sensex up 0.44% [6] - European shares were mixed, with the eurozone's STOXX 600 gaining 0.1%, while Germany's DAX 40 fell 0.3% and France's CAC 40 fell 0.2% [5] Company Financials - Verizon Communications reported mixed third-quarter results, with revenue growth of 1.5% year-over-year to $33.8 billion, missing analyst estimates of $34.3 billion, while adjusted EPS of $1.21 exceeded the consensus estimate of $1.19 [2] Commodity Prices - In commodity news, oil traded up 0.3% to $60.31, gold increased by 1% to $4,022.90, silver rose 1.6% to $48.075, and copper was up 1% to $5.2205 [4] Stock Movements - Cambium Networks Corp shares surged 209% to $1.91 after announcing integration with Starlink satellite Internet services [8] - Purple Biotech Ltd shares increased 118% to $1.27 following the achievement of a commercially viable yield for IM1240 [8] - Advent Technologies Holdings Inc shares dropped 51% to $1.33, while Stride Inc shares fell 47% to $82.04 due to second-quarter sales guidance below estimates [8] - Varonis Systems Inc shares fell 44% to $35.14 after reporting third-quarter revenue below estimates [8] Economic Indicators - U.S. mortgage application volume jumped by 7.1% from the previous week for the period ending October 17 [7]

Core Insights - Purple Biotech has achieved a commercially viable yield for IM1240, a tri-specific antibody targeting the tumor-associated antigen 5T4, positioning the program competitively for future development [1] - The CAPTN-3 platform has been validated for scalability, indicating its potential for developing complex tri-specific antibodies with competitive yield and purity [2] Company Overview - Purple Biotech Ltd. is a clinical-stage company focused on developing first-in-class therapies to overcome tumor immune evasion and drug resistance, with a pipeline that includes CAPTN-3, CM24, and NT219 [3] - IM1240 is the first tri-specific antibody in development targeting the 5T4 antigen, which is associated with advanced disease and poor clinical outcomes in various solid tumors [3] Technology and Mechanism - The CAPTN-3 platform generates conditionally activated tri-specific antibodies that engage both T cells and NK cells, inducing a strong localized immune response within the tumor microenvironment [2][3] - The technology incorporates a cleavable capping mechanism that confines therapeutic activity to the tumor microenvironment, potentially increasing the therapeutic window for patients [2][3] Clinical Development - An Investigational New Drug (IND) submission for IM1240 is planned for 2026, with the antibody advancing toward first-in-human clinical trials [1] - NT219 has demonstrated anti-tumor activity in combination with cetuximab in a Phase 1 study and is currently being evaluated in a Phase 2 study for recurrent and/or metastatic squamous cell carcinoma of the head and neck [4]

Core Points - Purple Biotech Ltd. has received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement, as the closing bid price for its American Depositary Shares (ADSs) has been below $1.00 for 30 consecutive trading days [1] - The company has a 180-day period until April 14, 2026, to regain compliance by achieving a closing bid price of $1.00 or more for at least ten consecutive business days [2] - The notification does not affect the company's current Nasdaq listing or trading of its ADSs, which will continue under the symbol "PPBT" [3] Compliance and Remediation - If compliance is not regained by April 14, 2026, the company may be eligible for an additional 180 days to cure the deficiency, provided it meets other listing requirements [4] - The company intends to monitor its ADS closing bid price and may consider options to regain compliance, including potentially changing the ADS to ordinary shares ratio [5] Company Overview - Purple Biotech is a clinical-stage company focused on developing first-in-class therapies to combat tumor immune evasion and drug resistance, with a pipeline that includes CAPTN-3, CM24, and NT219 [6] - CAPTN-3 is a preclinical platform utilizing tri-specific antibodies to enhance immune response within the tumor microenvironment, while CM24 is a humanized monoclonal antibody targeting CEACAM1 to block tumor immune evasion [6][7] - NT219 is a novel small molecule that targets IRS1/2 and STAT3, showing anti-tumor activity in combination with cetuximab in clinical studies [7]

Core Viewpoint - Purple Biotech Ltd. is advancing its clinical-stage therapies, particularly NT219, which targets tumor immune evasion and drug resistance, and has received an intention to grant a European Patent for its combination therapies [1][2][3] Company Overview - Purple Biotech is a clinical-stage company focused on developing first-in-class therapies to combat tumor immune evasion and drug resistance, with a pipeline that includes NT219, CAPTN-3, and CM24 [4] - The company is headquartered in Rehovot, Israel, and is publicly traded on NASDAQ and TASE under the ticker PPBT [4] Patent and Intellectual Property - The European Patent Office intends to grant a patent for NT219 combinations with leading immunotherapies, which could provide broad protection until 2036 [2] - The patent covers combinations of NT219 with various immunotherapies and chemotherapies, aimed at enhancing treatment sensitivity for resistant tumors [2] Clinical Development - A Phase 2 study for NT219 in combination with immunotherapy is underway, specifically targeting squamous cell carcinoma of the head and neck [3][5] - The study evaluates NT219 with pembrolizumab and cetuximab, building on previous Phase 1 results that showed anti-tumor activity [3][5] - Preclinical data supports the synergistic effects of NT219 with immunotherapy, indicating a shift in the tumor microenvironment from immunosuppressive to immunoreactive [3] Therapeutic Mechanism - NT219 functions as a dual inhibitor targeting IRS1/2 and STAT3, both of which are critical in drug resistance and tumor immune evasion [3][5] - The company is also developing CAPTN-3, a platform of tri-specific antibodies designed to enhance immune response within the tumor microenvironment [4]

Core Viewpoint - Purple Biotech Ltd. has successfully closed a public offering of 5,999,999 American Depositary Shares (ADSs) at a price of $1.00 per share, with additional short-term warrants potentially raising gross proceeds of approximately $12 million if fully exercised [1][3]. Group 1: Offering Details - The public offering included 5,999,999 ADSs, each representing 200 ordinary shares, and short-term warrants to purchase up to 11,999,998 ADSs [1]. - The gross proceeds from the offering were approximately $6 million before deducting fees and expenses [3]. - The short-term warrants have an exercise price of $1.00 per ADS and are exercisable immediately, expiring twenty-four months from issuance [1][3]. Group 2: Use of Proceeds - The net proceeds from the offering will be used for the development of oncology therapeutic candidates and for general working capital and corporate purposes [3]. Group 3: Company Overview - Purple Biotech is a clinical-stage company focused on developing first-in-class therapies to overcome tumor immune evasion and drug resistance [6]. - The company's oncology pipeline includes CAPTN-3, CM24, and NT219, with CAPTN-3 being a preclinical platform of conditionally activated tri-specific antibodies [6]. - CM24 is a humanized monoclonal antibody targeting CEACAM1, and NT219 is a dual inhibitor targeting IRS1/2 and STAT3, with ongoing clinical studies demonstrating anti-tumor activity [6].